New CAR-T therapy trial targets Tough-to-Treat blood cancers
NCT ID NCT06680752
Summary
This early-stage trial is testing the safety and effectiveness of an experimental treatment called ARD103 for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned after treatment or hasn't responded to standard therapies. ARD103 is a type of CAR-T cell therapy, where a patient's own immune cells are modified in a lab to better target and fight their cancer cells. The study will find the right dose and see how well the treatment works in controlling these aggressive blood cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novant Health Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novant Health Cancer Institute
RECRUITINGWinston-Salem, North Carolina, 27201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.